Mogamulizumab, an anti-CCR4 monoclonal antibody, exhibits clinical activity in CCR4+ systemic and cutaneous T-cell lymphomas, and may be of some benefit in contrasting the cHL microenvironment [29]. This evidence concerns the gene CCR4 and classic Hodgkin lymphoma.